ORIC’s senior management team has decades of experience in the biotech and pharmaceutical industries, having worked in drug discovery and development at companies such as Merck, Pfizer and Genentech.
Richard Heyman, Ph.D.
Chief Executive Officer
Dr. Heyman is a biopharmaceutical executive with over 25 years of experience in the industry. Most recently he served as CEO of Seragon Pharmaceuticals, a company focused on the development of drugs targeting hormone dependent cancers that was acquired by the Roche group. He was also co-founder and CEO of Aragon Pharmaceuticals, which was purchased by Johnson & Johnson in 2013. Previously, he co-founded and served as Chief Scientific Officer of X-Ceptor Therapeutics, a company that developed compounds targeting nuclear receptors for the treatment of metabolic diseases, acquired by Exelixis in 2004. As Vice President of Research at Ligand Pharmaceuticals, he led the development of Panretin® and Targretin®, retinoids approved by the FDA for the treatment of cancer. He is the author or inventor on more than 120 publications and patents. Dr. Heyman serves on the Board of Directors for BIOCOM, Organovo Inc., The Jenna Druck Center, and is a member of the Therapeutic Advisory Board for aTyr Pharma. He was a NIH postdoctoral fellow at the Salk Institute and received a Ph.D. in pharmacology from the University of Minnesota. He completed his B.S. in chemistry from the University of Connecticut.
Valeria Fantin, Ph.D.
Chief Scientific Officer
Dr. Fantin is a biopharmaceutical leader with over a decade of experience in exploratory biology and oncology drug discovery and development. Prior to joining ORIC, she was Vice President of Tumor Cell Biology at Pfizer, responsible for advancing small molecules from target validation to Phase 2 proof-of-concept. Dr. Fantin was also responsible for identifying business development opportunities and leading strategic alliances to broaden Pfizer’s efforts in oncology research.
Prior to joining Pfizer, Dr. Fantin held leadership positions at Agios Pharmaceuticals where she created and advanced an exploratory program of novel cancer metabolism targets into drug discovery, and led the execution of the company’s flagship isocitrate dehydrogenase program. Her earlier career as a researcher included positions focused on epigenetics and kinase drug discovery projects with Merck Research Laboratories and ARIAD Pharmaceuticals. She has contributed to the discovery of numerous compounds currently under clinical evaluation and the development of Zolinza® (vorinostat) and Ibrance® (palbociclib).
Dr. Fantin was awarded the Rising Star Award by the Healthcare Businesswomen’s Association. Dr. Fantin completed postdoctoral training in cancer metabolism and signal transduction at Harvard Medical School and the Howard Hughes Medical Institute, and earned her Ph.D. in molecular and cellular biology from Dartmouth Medical School.
Leonard Reyno, M.D.
Chief Medical Officer
Prior to joining ORIC, Leonard Reyno served as Senior Vice President and Chief Medical Officer at Agensys, a subsidiary of Astellas Pharma, where he led clinical stage development through clinical proof of concept. Dr. Reyno’s prior positions in industry included Global Medical Director for Taxotere/Breast cancer at Aventis, Medical Director and Lead Clinical Scientist for Herceptin at Genentech and Senior Director of Oncology at Cytokinetics.
Before joining industry, Dr. Reyno was an academic oncologist, where he had both extensive experience as a clinician (especially in breast and genitor-urinary malignancy) as well as serving as Principal Investigator on multiple trials with the National Cancer Institute of Canada. Dr. Reyno was Head of Medical Oncology and the Oncology Clinical Research Unit at Dalhousie University from 1999- 2003, and previously Associate Professor of Medicine at McMaster University from 1993-1999.
Dr. Reyno received his M.D. from McMaster University in 1986. He completed fellowships in internal medicine and medical oncology at McMaster and further training in drug development at the University of Maryland at Baltimore as the McEachern Fellow of the National Cancer Institute of Canada from 1991-1993. He has authored more than 25 scientific publications in major journals.
Vice President, Human Resources
Brian Muma has a broad background in human resources with deep understanding of the biopharmaceutical industry acquired from HR leadership positions across the spectrum from discovery to commercialization. Mr. Muma was previously Vice President of Human Resources for Roche China. Prior to the assignment in China, Brian held senior HR leadership roles at Genentech in R&D, Manufacturing, Commercial Operations and Total Rewards Strategy. Earlier in his career, he was an executive compensation consultant at KPMG and Mercer.
Mr. Muma has completed certification courses in change management, advanced project management and 360 degree feedback as well as advanced training in executive coaching and emotional intelligence. He holds a Bachelors degree in Economics and an MBA from the University of Michigan.
General Counsel, Corporate Secretary, and Senior Director of Business Development
Krys Corbett has more than 20 years of experience in licensing transactions, business development and alliance management, including more than 15 in biopharma.
In previous roles at Genentech and Roche, Ms. Corbett focused on strategic alliances and transactions in Roche Partnering, Genentech Alliance Management and Portfolio Planning, and Genentech Transactional Law. She led transactions for licensing, launch or label expansions of Venclexta®, Lucentis®, Rituxan Hycela®, Erivedge®, and development-stage assets, and provided legal and partnering support for products including Avastin®, Xolair®, Rituxan®, and Cotellic®.
Prior to Genentech/Roche, she was at Wilson Sonsini Goodrich and Rosati, where she advised clients on licensing and M&A transactions. She received her J.D. with honors from Duke University School of Law.
Director of Finance & Operations
Sara Coblin previously worked as Director of Finance at Genentech supporting global CMC operations. Prior to that role, she held other finance positions in R&D, FP&A and Alliance Management supporting partnerships on Ocrevus®, Rituxan®, Tarceva® and many other pipeline programs. Earlier in her career, she worked at Sun Microsystems and Arthur Andersen specializing in business process improvement and ERP systems implementation.
Ms. Coblin is a certified Six Sigma Green Belt. She holds a BA in Economics and Computer Applications from the University of Notre Dame. She also earned an MBA from University of California, Berkeley.
Jennifer Low, Ph.D., M.D.
Clinical Strategy Consultant
Jennifer Low has extensive drug development industry experience, most recently as the Chief Medical Officer and Executive Vice President, Research and Development at Loxo Oncology. Prior to that she was Senior Group Director in oncology development at Genentech, where she oversaw the Erivedge (Hedgehog), Zelboraf (B-raf), Cotellic (Mek), and Tarceva (EGFR) programs. She has co-authored papers appearing in the New England Journal of Medicine and Science and numerous oncology journals.
She received her undergraduate degree from Caltech, her M.D. and Ph.D. degrees from Georgetown, and completed her internal medicine residency at UC Davis, medical oncology fellowship at the National Cancer Institute, and was a Senior Investigator at the Cancer Therapeutics Evaluation Program (CTEP) at NCI and an attending physician in breast cancer at NIH and the National Naval Medical Center in Bethesda.